目的 探討肺力咳合劑聯(lián)合復方異丙托溴銨治療嬰幼兒急性支氣管炎肺炎的臨床療效和安全性。方法 選取2016年3月-2017年3月在鄭州兒童醫(yī)院治療的急性支氣管炎肺炎患兒115例，根據(jù)用藥的差別分成對照組（57例）和治療組（58例）。對照組患兒霧化吸入吸入用復方異丙托溴銨溶液，3~4次/d，2.5 mL/d；治療組患兒在對照組基礎(chǔ)上口服肺力咳合劑，10 mL/次，3次/d。兩組患兒均經(jīng)過7 d治療。觀察兩組患兒臨床療效，比較治療前后兩組患兒臨床癥狀緩解情況、肌鈣蛋白I（cTnI）、降鈣素（PCT）和超敏C-反應蛋白（hs-CRP）水平以及血氣指標和不良反應情況。結(jié)果 治療后，對照組和治療組臨床總有效率分別為82.46%和96.55%。兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，治療組患兒臨床癥狀緩解時間和住院時間均顯著短于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患兒cTnI、PCT和hs-CRP血清水平均顯著降低（P<0.05）；且治療組上述指標水平比對照組更低（P<0.05）。治療后，兩組患兒SaO₂和pO₂顯著升高，pCO₂顯著降低，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組血氣指標顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療期間，治療組患兒不良反應發(fā)生率顯著低于對照組患兒，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 肺力咳合劑聯(lián)合復方異丙托溴銨治療急性支氣管炎肺炎臨床療效好，不良反應少，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy and safety of Feilike Mistura combined with compound ipratropium bromide in treatment of infantile with acute bronchopneumonia. Methods Infantile (115 cases) with acute bronchopneumonia in Zhengzhou Children's Hospital from March 2016 to March 2017 were randomly divided into control (57 cases) and treatment (58 cases) groups according to different treatment. Infantile in the control group were atomization inhalation administered with Compound Ipratropium Bromide Solution for inhalation, 3-4 times/d, 2.5 mL/d. Infantile in the treatment group were po administered with Feilike Mistura on the basis of the control group, 10 mL/time, three times daily. Infantile in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the alleviative time of clinical symptoms, cTnI, PCT and hs-CRP levels, blood gas indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.46% and 96.55%, respectively, and there were differences between two groups (P < 0.05). After treatment, the alleviative time of clinical symptoms and the hospitalization time in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the cTnI, PCT and hs-CRP levels in two groups were significantly decreased (P < 0.05), and these indexes levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the SaO₂ and pO₂ in two groups were significantly increased, but pCO₂was significantly decreased, and there were differences in the same group (P < 0.05). And the blood gas indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Feilike Mistura combined with compound ipratropium bromide has good clinical efficacy and less adverse reactions in treatment of infantile with acute bronchopneumonia, which has a certain clinical application value.